PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $42 | $28 | $74 | $61 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $1 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $7 | $12 | $4 | $1 |
| Total Curr. Assets | $49 | $40 | $79 | $63 |
| Property Plant & Equip (Net) | $12 | $10 | $4 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $12 | $10 | $4 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $61 | $50 | $82 | $63 |
| Liabilities | – | – | – | – |
| Payables | $13 | $4 | $3 | $2 |
| Short-Term Debt | $5 | $5 | $2 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $2 | $0 | $0 | $0 |
| Other Curr. Liab. | $8 | $6 | $3 | $3 |
| Total Curr. Liab. | $28 | $15 | $8 | $5 |
| LT Debt | $2 | $7 | $12 | $8 |
| Deferred Rev, NC | $8 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $116 | $54 | $2 | $0 |
| Total NC Liab. | $126 | $61 | $14 | $8 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $154 | $76 | $23 | $12 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $63 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$392 | -$261 | -$162 | -$123 |
| AOCI | $0 | $0 | -$2 | -$2 |
| Other Equity | $299 | $235 | $224 | $113 |
| Total Equity | -$93 | -$25 | $60 | $51 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $61 | $50 | $82 | $63 |
| Net Debt | -$34 | -$16 | -$59 | -$54 |